Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Bicycle Therapeutics plc BCYC
$24.06
+$1.1 (4.56%)
На 18:01, 12 мая 2023
+193.02%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
692502675.00000000
-
week52high
33.49
-
week52low
12.08
-
Revenue
14463000
-
P/E TTM
-6
-
Beta
0.74746800
-
EPS
-4.20000000
-
Last Dividend
0.00000000
-
Next Earnings Date
05 мая 2023 г. в 12:30
Описание компании
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cowen & Co. | Outperform | 31 авг 2022 г. | |
| SVB Leerink | Outperform | Outperform | 22 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 05 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 05 авг 2022 г. |
| Barclays | Overweight | 28 июл 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 12 сент 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 09 ноя 2022 г. |
| EF Hutton | Buy | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Jordan Veronica GH | A | 11500 | 11500 | 03 янв 2023 г. |
| Jordan Veronica GH | A | 10750 | 5750 | 03 янв 2023 г. |
| Crockett Nigel | A | 35000 | 35000 | 03 янв 2023 г. |
| Crockett Nigel | D | 30699 | 1801 | 03 янв 2023 г. |
| Crockett Nigel | A | 32500 | 17500 | 03 янв 2023 г. |
| Winter Gregory Paul | A | 11500 | 11500 | 03 янв 2023 г. |
| Winter Gregory Paul | A | 174677 | 5750 | 03 янв 2023 г. |
| Milnes Alistair | A | 35000 | 35000 | 03 янв 2023 г. |
| Milnes Alistair | D | 38179 | 1801 | 03 янв 2023 г. |
| Milnes Alistair | A | 39980 | 17500 | 03 янв 2023 г. |
Новостная лента
Wall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a Bet
Zacks Investment Research
04 мая 2023 г. в 11:26
The consensus price target hints at a 146.3% upside potential for Bicycle Therapeutics PLC Sponsored ADR (BCYC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bicycle (BCYC) up on Collaboration With Novartis for Conjugates
Zacks Investment Research
29 мар 2023 г. в 09:59
Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
Business Wire
11 янв 2023 г. в 07:00
CAMBRIDGE, England, & BOSTON--( BUSINESS WIRE )--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ®) technology, today announced that monotherapy dose escalation results of the ongoing Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, will be presented at the 2023 American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, being held February 16-18, 2023 in San Francisco, California. On Tuesday, February 14, 2023 at 8:00 a.m. ET, the Company will host a conference call with BT8009 investigator Dr. Capucine Baldini (Medical Oncologist, Gustave Roussy) and Dr. Daniel Petrylak (Professor of Medicine and Genitourinary Oncology, Yale School of Medicine) to discuss the data being presented.
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
Business Wire
10 ноя 2022 г. в 09:09
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that preclinical data for BT7480, a novel Bicycle tumor-targeted immune cell agonist (Bicycle TICA), and BT7455, an EphA2/CD137 Bicycle TICA, will be presented in five poster presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Ann
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Business Wire
06 сент 2022 г. в 07:00
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13th, 2022 at 10:00 a.m. ET. A live webcast of the fireside chat will be accessible in the Investors and Media section o